Florbetapir F18

DRUG3 trials

Sponsors

Eli Lilly & Co., Avid Radiopharmaceuticals, Sanofi

Conditions

Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental DisordersAlzheimers DiseaseDementia Alzheimer's Type

Phase 2

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

WithdrawnNCT02667496

SanofiDementia Alzheimer's Type

Start: 2016-11-30End: 2017-03-31Updated: 2017-04-07

Phase 3

I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

RecruitingCTIS2025-522340-40-00

Eli Lilly & Co.Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

Start: 2025-12-04Target: 170Updated: 2026-01-19

Phase 4

The Feasibility of Florbetapir Quantitation

CompletedNCT01946243

Avid RadiopharmaceuticalsAlzheimers Disease

Start: 2013-08-31End: 2014-04-30Updated: 2015-06-29